These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11343038)

  • 1. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism.
    Coniglio SJ; Lewis JD; Lang C; Burns TG; Subhani-Siddique R; Weintraub A; Schub H; Holden EW
    J Pediatr; 2001 May; 138(5):649-55. PubMed ID: 11343038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
    Sandler AD; Sutton KA; DeWeese J; Girardi MA; Sheppard V; Bodfish JW
    N Engl J Med; 1999 Dec; 341(24):1801-6. PubMed ID: 10588965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism.
    Owley T; McMahon W; Cook EH; Laulhere T; South M; Mays LZ; Shernoff ES; Lainhart J; Modahl CB; Corsello C; Ozonoff S; Risi S; Lord C; Leventhal BL; Filipek PA
    J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1293-9. PubMed ID: 11699803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of transdermal secretin on behavior of children with autism.
    Ratliff-Schaub K; Carey T; Reeves GD; Rogers MA
    Autism; 2005 Jul; 9(3):256-65. PubMed ID: 15937041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials.
    Sturmey P
    Res Dev Disabil; 2005; 26(1):87-97. PubMed ID: 15590241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.
    Lightdale JR; Hayer C; Duer A; Lind-White C; Jenkins S; Siegel B; Elliott GR; Heyman MB
    Pediatrics; 2001 Nov; 108(5):E90. PubMed ID: 11694674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double-Blind, Placebo-Controlled Trial of Secretin for the Treatment of Autistic Disorder.
    Owley T; Steele E; Corsello C; Risi S; McKaig K; Lord C; Leventhal BL; Cook Jr EH
    MedGenMed; 1999 Oct; ():E2. PubMed ID: 11104404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.
    Fankhauser MP; Karumanchi VC; German ML; Yates A; Karumanchi SD
    J Clin Psychiatry; 1992 Mar; 53(3):77-82. PubMed ID: 1548248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of benefit of intravenous synthetic human secretin in the treatment of autism.
    Molloy CA; Manning-Courtney P; Swayne S; Bean J; Brown JM; Murray DS; Kinsman AM; Brasington M; Ulrich CD
    J Autism Dev Disord; 2002 Dec; 32(6):545-51. PubMed ID: 12553591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of secretin on children with autism: a randomized controlled trial.
    Dunn-Geier J; Ho HH; Auersperg E; Doyle D; Eaves L; Matsuba C; Orrbine E; Pham B; Whiting S
    Dev Med Child Neurol; 2000 Dec; 42(12):796-802. PubMed ID: 11132252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin.
    Levy SE; Souders MC; Wray J; Jawad AF; Gallagher PR; Coplan J; Belchic JK; Gerdes M; Mitchell R; Mulberg AE
    Arch Dis Child; 2003 Aug; 88(8):731-6. PubMed ID: 12876177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism.
    Unis AS; Munson JA; Rogers SJ; Goldson E; Osterling J; Gabriels R; Abbott RD; Dawson G
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1315-21. PubMed ID: 12410073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone and communication skills in young children with autism.
    Feldman HM; Kolmen BK; Gonzaga AM
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):587-93. PubMed ID: 10230191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.
    Corbett B; Khan K; Czapansky-Beilman D; Brady N; Dropik P; Goldman DZ; Delaney K; Sharp H; Mueller I; Shapiro E; Ziegler R
    Clin Pediatr (Phila); 2001 Jun; 40(6):327-31. PubMed ID: 11824175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial.
    Roberts W; Weaver L; Brian J; Bryson S; Emelianova S; Griffiths AM; MacKinnon B; Yim C; Wolpin J; Koren G
    Pediatrics; 2001 May; 107(5):E71. PubMed ID: 11331721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved social and language skills after secretin administration in patients with autistic spectrum disorders.
    Horvath K; Stefanatos G; Sokolski KN; Wachtel R; Nabors L; Tildon JT
    J Assoc Acad Minor Phys; 1998; 9(1):9-15. PubMed ID: 9585670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.